The Global Cancer Monoclonal Antibodies Market size in 2023 is USD 53.33 billion. The market share is projected to grow at a CAGR of 14.00% and reach USD 133.45 billion by 2031.
Global Cancer Monoclonal Antibodies Market - Industry Overview
The global cancer monoclonal antibodies market is expected to rise significantly over the course of the projected period. This market rise is largely being driven by the increasing frequency of solid malignancies such as cancer. Further driving the market's expansion are factors including the growing frequency of immunological disorders brought on by family history and the pervasive adoption of unhealthy lifestyles. The COVID-19 pandemic has also contributed significantly to the market's acceleration of growth.
Data Bridge Market Research Market Report provides details of new recent developments, market share, market trends on the basis of its segmentations and regional analysis, the impact of market players, analyses of opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the market, contact Data Bridge Market Research’s team of expert analysts. Our team will help you make informed market decisions to achieve business growth.
Global Cancer Monoclonal Antibodies Market Size
|
Global Cancer Monoclonal Antibodies Report Metric Details
|
|
||
|
Report Metric
|
Details
|
||
|
Forecast Period
|
2024-2031
|
||
|
Base Year
|
2024
|
||
|
Historic Year
|
2023 (Customizable 2016-2021)
|
||
|
Measuring Unit
|
USD Billion
|
||
|
Data Pointers
|
Market value, growth rate, market segments, geographical coverage, market players, and market scenario, in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
||
The shift towards personalized medicine, where treatments are tailored to individual genetic profiles, is driving innovation within the global cancer monoclonal antibodies market. As healthcare systems globally prioritize early diagnosis and effective management of cancer, the role of monoclonal antibodies has become more prominent. The market is also benefiting from a growing aging population and lifestyle factors, such as increased exposure to carcinogens, which have led to a higher incidence of cancer. As a result Databridge Market Research dived into comprehensively analyzing the market and unveiled that the Global Cancer Monoclonal Antibodies Market is increasing at a CAGR of 14.00%. Our detailed analysis forecasts that the market is valued at USD 53.33 billion in 2023 and is expected to grow upto USD 133.45 billion by 2031. Our meticulously created report, developed through comprehensive research and analytics, is a distinguished paper that unveils eye-opening data about the market.
Global Cancer Monoclonal Antibodies Market Dynamics
Global Cancer Monoclonal Antibodies Market Growth Drivers
Increase in Cancer Cases
According to the National Cancer Institute (NCI), nearly 20 billion new cancer cases and 9.7 billion cancer-related deaths occurred globally in 2022. These figures are projected to increase dramatically by 2040, with 29.9 billion new cases and 15.3 billion deaths annually. The escalating burden of cancer cases underscores the urgent need for effective cancer treatments, such as monoclonal antibodies, which are increasingly adopted for their precision and efficacy in targeting cancer cells, thereby propelling global cancer monoclonal antibodies market growth.
Advancements in biotechnology
Advancements in biotechnology have revolutionized the development and effectiveness of monoclonal antibodies, making them a cornerstone in modern cancer therapy. For instance Trastuzumab emtansine (Kadcyla), used for HER2-positive breast cancer, has demonstrated improved survival rates and reduced systemic toxicity compared to traditional chemotherapy.
Global Cancer Monoclonal Antibodies Market growth Opportunities
Rising awareness
Governments worldwide are launching campaigns to raise awareness about cancer. For instance, the World Health Organization's "World Cancer Day" campaign, observed every year on February 4th, reaches billions of people globally, spreading awareness about prevention, early detection, and treatment options. As awareness efforts continue to educate the public and healthcare providers about the benefits of early intervention, the demand for effective and targeted therapies like monoclonal antibodies is expected to rise. Growing awareness amplifies the potential for global cancer monoclonal antibodies market.
Increase in ageing population
According to the United Nations, the proportion of the global population aged 65 and more is predicted to climb from 10% in 2022 to 16% in 2050. The generational transition is predicted to increase the incidence of cancer, given the chance of developing cancer increases with age. Consequently, there will be an increased demand for advanced and targeted medicines, such as monoclonal antibodies, to effectively control and treat cancer in an older population.
Global Cancer Monoclonal Antibodies Market growth Challenges
High Cost of Therapy
Monoclonal antibodies are often expensive to develop and administer, leading to high costs for patients and healthcare systems. For instance, treatments like Trastuzumab (Herceptin) can cost tens of thousands of dollars annually. High costs limits accessibility and affordability, creating barriers for widespread adoption and posing a challenge to global cancer monoclonal antibodies market growth.
Lack of technical skills.
A significant challenge for the global cancer monoclonal antibodies market is the shortage of skilled professionals. The development and administration of these therapies require specialized expertise in biotechnology and clinical oncology. For instance, the U.S. Bureau of Labor Statistics reports a projected 13% growth in the demand for medical scientists from 2021 to 2031, indicating a shortage of skilled professionals in this field.
Global Cancer Monoclonal Antibodies Market Restraints
Increased regulations constraining the growth of the global Cancer Monoclonal Antibodies market
The approval process for new therapies is both rigorous and time-consuming, requiring extensive clinical trials and adherence to stringent regulations. For instance, the development of the monoclonal antibody drug Pembrolizumab (Keytruda) involved several phases of clinical trials to demonstrate its safety and efficacy in treating various cancers. The entire process took over a decade from initial research to regulatory approval by the U.S. FDA in 2014. Such lengthy and costly regulatory requirements act as a restraint for the global cancer monoclonal antibodies market.
Global Cancer Monoclonal Antibodies Market Scope and Trends
|
Global Cancer Monoclonal Antibodies Market Segmentations Overview
|
|
|
Market
|
Sub-Segments
|
|
Application
|
Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Solid Tumor, Epithelial Tumor, Others
|
|
Route of Administration
|
Parenteral, Others
|
|
End-Users
|
Hospitals, Specialty Clinics, Homecare, Others
|
|
Distribution Channel
|
Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others
|
- New targeted medicines have been developed to treat AML cells with specific genetic alterations and abnormalities. Idhifa (enasidenib), a medication that targets IDH2 mutations, and Venclexta (venetoclax), which targets BCL-2 proteins, have both shown encouraging outcomes in clinical trials.
- Ibrutinib (Imbruvica) and Acalabrutinib (Calquence) have become important in the treatment of Chronic Lymphocytic Leukemia (CLL). Discussed drugs work by inhibiting the BTK enzyme, which is crucial for the survival and proliferation of Chronic Lymphocytic Leukemia (CLL) cells.
- Advances in genomic sequencing are enabling more precise identification of mutations and alterations in solid tumors. Genetic information guides the use of targeted therapies and personalized treatment plans, improving outcomes and reducing unnecessary side effect.
- Combining therapies such as chemotherapy with targeted or immunotherapy is increasingly common. For instance, combining Checkpoint Inhibitors with Chemotherapy is showing promising results in treating epithelial tumors such as NSCLC and bladder cancer.
Global Cancer Monoclonal Antibodies Market Regional Analysis – Market Trends
|
Global Cancer Monoclonal Antibodies Market Regional Overview
|
|
|
|
Region
|
Countries
|
|
|
Europe
|
Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe
|
|
|
APAC
|
China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific
|
|
|
North America
|
U.S., Canada, and Mexico
|
|
|
MEA
|
Saudi Arabia, U.A.E., South Africa, Egypt, Israel, Rest of Middle East, and Africa
|
|
|
South America
|
Brazil, Argentina, and Rest of South America
|
|
Key Insights
- The North American cancer monoclonal antibodies market is dominated by the United States and Canada, driven by a high incidence of cancer, advanced healthcare infrastructure, and significant investments in research and development. The region benefits from a robust regulatory environment, with the U.S. FDA’s approval of leading therapies like Pembrolizumab (Keytruda) and Nivolumab (Opdivo) reinforcing its market leadership.
- In Europe, strong healthcare systems, favorable regulatory frameworks, and increasing cancer awareness drive market growth. The European Medicines Agency (EMA) supports the market with its regulatory approvals, and initiatives like Horizon 2020 enhance R&D efforts. The widespread adoption of therapies such as Trastuzumab (Herceptin) and Bevacizumab (Avastin) highlights the region’s key role in the global market.
- The Asia-Pacific region, led by China, Japan, and India, is experiencing rapid growth in the cancer monoclonal antibodies market, driven by significant factors such as expanding healthcare infrastructure, rising cancer incidence, and increasing healthcare expenditure. In China, the approval of new therapies like Sintilimab (a PD-1 inhibitor) underscores the country’s growing market for advanced cancer treatments. Additionally, India’s increasing healthcare investments and growing pharmaceutical sector are contributing to the market’s expansion.
- The cancer monoclonal antibodies market in the Middle East and Africa is expanding, with South Africa, Saudi Arabia, and the UAE at the forefront. In South Africa, initiatives such as the South African National Cancer Registry are improving cancer detection and treatment access. Saudi Arabia’s Vision 2030 plan includes substantial investments in healthcare infrastructure and cancer care, leading to the development of advanced oncology centers such as King Fahd Medical City.
Global Cancer Monoclonal Antibodies Market Leading Players
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Mylan N.V. (U.S.)
- Sanofi (France)
- Pfizer Inc. (U.S.)
- GSK plc (U.K.)
- Novartis AG (Switzerland)
- Bayer AG (Germany)
- Lilly (U.S.)
- Merck & Co., Inc. (U.S.)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Fresenius Kabi AG (Germany)
- Akorn Incorporated (U.S.)
- Teva Pharmaceutical Industries Ltd (Israel)
Global Cancer Monoclonal Antibodies Market Recent Developments
- In February, 2024 Scientists at Tohoku University develop a new monoclonal antibody to treat HER2-positive breast cancer.
- In April, 2024, Approval of Elahere by U.S. Food and Drug Administration Expands Treatment Options for Platinum-resistant ovarian Cancers whose tumors produce an excessive amount of a protein called FR-α.
- Researchers from Children's Hospital of Philadelphia (CHOP) and the Perelman School of Medicine at the University of Pennsylvania (Penn) discovered that gene splicing within cancer cells might result in large variations in CD20 protein levels, rendering therapies ineffective.
- In August, 2024 GlycoNex, a clinical-stage biotechnology firm focused on the development of glycan-directed cancer medicines, reported the successful completion of a Phase 1 clinical trial for its denosumab biosimilar, SPD8, developed in conjunction with Mitsubishi Gas Chemical firm, Inc.
SKU-